Lisata Therapeutics (CALADRIUS BIOSCIENCES)

In News

CDMO Catalent strengthens ADC pipeline with $10M pact for Lisata tumor drug - Fierce Biotech

Fierce Biotech - Oct 09, 2025

Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics - GlobeNewswire

GlobeNewswire - Sep 15, 2022

Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics - Yahoo Finance

Yahoo Finance - Sep 14, 2022

Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics - citybiz

citybiz - Sep 14, 2022

2 become 1: Caladrius and Cend merge into tumor-focused Lisata Therapeutics - Fierce Biotech

Fierce Biotech - Apr 27, 2022

New Publicly Traded Therapeutics Innovator Emerges from Merger - Procopio

Procopio - Sep 15, 2022

Caladrius Biosciences to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 22, 2022, at 4:30 p.m. Eastern Time - Stock Titan

Stock Titan - Mar 15, 2022

Top Biomedical Award Given to Scientist for Breakthrough Cancer-Fighting Discovery - Procopio

Procopio - Sep 29, 2022

Supply chain challenges upend Caladrius' coronary artery disease trial - Fierce Biotech

Fierce Biotech - May 24, 2022

Global Artificial Blood Vessels Market to Surpass 3 Billion Mark by 2030 | DelveInsight - PR Newswire UK

PR Newswire UK - Jun 13, 2024

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment